


DOCKET NO. 3840-005-27



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Lakshman R. SEHGAL et al.

ART UNIT: 1643

SERIAL NO.: 10/725,013

EXAMINER:

FILING DATE: December 2, 2003

FOR: *EX VIVO* AND *IN VIVO* EXPRESSION OF THE THROMBOMODULIN
GENE FOR THE TREATMENT OF CARDIOVASCULAR AND
PERIPHERAL VASCULAR DISEASES

STATEMENT UNDER 37 CFR 1.821 - 1.825

BOX SEQUENCE

ASSISTANT COMMISSIONER FOR PATENTS

PO BOX 1450

ALEXANDRIA, VA 22313-1450

SIR:

The undersigned declares as follows:

1. That the contents of the attached paper copy of the sequence listing and the computer readable copy of the sequence listing submitted in accordance with 37 CFR 1.821(c) and (e), respectively are the same in compliance with 1.821(f).
2. That the submission herein, filed in accordance with 37 CFR 1.821(g), does not include new matter.

Respectfully submitted,
PIPER BUDNICK LLP

Steven B. Kelber
Registration No. 30,073
Attorney of Record

1200 Nineteenth Street, N.W.
Washington, D.C. 20036-2412
Telephone No. (202) 861-3900
Facsimile No. (202) 223-2085

Ping Wang, M.D.
Registration No. 48,328